O	0	3	The
O	4	11	effects
O	12	14	of
B-intervention	15	24	poloxamer
I-intervention	25	28	and
I-intervention	29	35	sodium
I-intervention	36	44	alginate
I-intervention	45	52	mixture
O	53	54	(
O	54	61	Guardix
O	61	62	-
O	62	64	SG
O	64	65	®
O	65	66	)
O	67	69	on
B-condition	70	75	range
I-condition	76	78	of
I-condition	79	85	motion
O	86	91	after
O	92	100	axillary
O	101	106	lymph
O	107	111	node
O	112	122	dissection
O	122	123	:
O	124	125	A
O	126	132	single
O	132	133	-
O	133	139	center
O	139	140	,
O	141	152	prospective
O	152	153	,
O	154	164	randomized
O	164	165	,
O	166	172	double
O	172	173	-
O	173	178	blind
O	179	184	pilot
O	185	190	study
O	190	191	.

O	192	202	Restricted
O	203	211	shoulder
O	212	220	mobility
O	221	223	is
O	224	225	a
O	226	231	major
O	232	237	upper
O	238	247	extremity
O	248	259	dysfunction
O	260	270	associated
O	271	275	with
O	276	281	lower
O	282	289	quality
O	290	292	of
O	293	297	life
O	298	301	and
O	302	312	disability
O	313	318	after
O	319	325	breast
O	326	332	cancer
O	333	340	surgery
O	340	341	.

O	342	344	We
O	345	357	hypothesized
O	358	362	that
O	363	364	a
O	365	374	poloxamer
O	375	378	and
O	379	385	sodium
O	386	394	alginate
O	395	402	mixture
O	403	404	(
O	404	411	Guardix
O	411	412	-
O	412	414	SG
O	414	415	®
O	415	416	)
O	417	424	applied
O	425	430	after
O	431	439	axillary
O	440	445	lymph
O	446	450	node
O	451	461	dissection
O	462	463	(
O	463	467	ALND
O	467	468	)
O	469	474	would
O	475	488	significantly
O	489	496	improve
O	497	505	shoulder
O	506	511	range
O	512	514	of
O	515	521	motion
O	522	523	(
O	523	526	ROM
O	526	527	)
O	528	530	in
O	531	539	patients
O	540	544	with
O	545	551	breast
O	552	558	cancer
O	558	559	.

O	560	562	We
O	563	572	conducted
O	573	574	a
O	575	581	double
O	581	582	-
O	582	587	blind
O	587	588	,
O	589	599	randomized
O	599	600	,
O	601	612	prospective
O	613	618	study
O	619	621	to
O	622	630	evaluate
O	631	634	the
O	635	643	clinical
O	644	652	efficacy
O	653	656	and
O	657	663	safety
O	664	666	of
O	667	674	Guardix
O	674	675	-
O	675	677	SG
O	677	678	®
O	679	682	for
O	683	686	the
O	687	697	prevention
O	698	700	of
O	701	706	upper
O	707	716	extremity
O	717	728	dysfunction
O	729	734	after
O	735	739	ALND
O	739	740	.

O	741	744	The
O	745	752	primary
O	753	760	outcome
O	761	768	measure
O	769	772	was
B-outcome-Measure	773	781	shoulder
I-outcome-Measure	782	785	ROM
I-outcome-Measure	786	788	at
I-outcome-Measure	789	797	baseline
I-outcome-Measure	798	799	(
I-outcome-Measure	799	801	T0
I-outcome-Measure	801	802	)
I-outcome-Measure	803	806	and
I-outcome-Measure	807	808	3
I-outcome-Measure	809	810	(
I-outcome-Measure	810	812	T1
I-outcome-Measure	812	813	)
I-outcome-Measure	813	814	,
I-outcome-Measure	815	816	6
I-outcome-Measure	817	818	(
I-outcome-Measure	818	820	T2
I-outcome-Measure	820	821	)
I-outcome-Measure	821	822	,
I-outcome-Measure	823	826	and
I-outcome-Measure	827	829	12
I-outcome-Measure	830	836	months
I-outcome-Measure	837	838	(
I-outcome-Measure	838	840	T3
I-outcome-Measure	840	841	)
I-outcome-Measure	842	847	after
I-outcome-Measure	848	855	surgery
O	855	856	.

O	857	866	Secondary
O	867	874	outcome
O	875	883	measures
O	884	888	were
O	889	892	the
B-outcome-Measure	893	905	Disabilities
I-outcome-Measure	906	908	of
I-outcome-Measure	909	912	the
I-outcome-Measure	913	916	Arm
I-outcome-Measure	916	917	,
I-outcome-Measure	918	926	Shoulder
I-outcome-Measure	926	927	,
I-outcome-Measure	928	931	and
I-outcome-Measure	932	936	Hand
I-outcome-Measure	937	942	score
I-outcome-Measure	942	943	(
I-outcome-Measure	943	947	DASH
I-outcome-Measure	947	948	)
O	948	949	,
B-outcome-Measure	950	954	pain
I-outcome-Measure	955	965	associated
I-outcome-Measure	966	970	with
I-outcome-Measure	971	979	movement
O	979	980	,
O	981	986	which
O	987	990	was
O	991	999	assessed
O	1000	1005	using
O	1006	1007	a
O	1008	1015	numeric
O	1016	1022	rating
O	1023	1028	scale
O	1028	1029	,
O	1030	1033	and
B-outcome-Measure	1034	1044	lymphedema
O	1045	1053	assessed
O	1054	1059	using
O	1060	1064	body
O	1065	1076	composition
O	1077	1085	analyzer
O	1085	1086	.

O	1087	1088	A
O	1089	1094	total
O	1095	1097	of
B-total-participants	1098	1100	83
B-eligibility	1101	1106	women
I-eligibility	1107	1111	with
I-eligibility	1112	1118	breast
I-eligibility	1119	1125	cancer
O	1126	1130	were
O	1131	1139	randomly
O	1140	1148	assigned
O	1149	1151	to
O	1152	1158	either
O	1159	1162	the
O	1163	1170	Guardix
O	1170	1171	-
O	1171	1173	SG
O	1173	1174	®
O	1175	1180	group
O	1181	1183	or
O	1184	1187	the
B-control	1188	1195	control
I-control	1196	1201	group
O	1201	1202	.

O	1203	1205	In
O	1206	1209	the
O	1210	1217	Guardix
O	1217	1218	-
O	1218	1220	SG
O	1220	1221	®
O	1222	1227	group
O	1228	1229	(
O	1229	1230	n
O	1231	1232	=
B-intervention-participants	1233	1235	37
O	1235	1236	)
O	1236	1237	,
O	1238	1245	Guardix
O	1245	1246	-
O	1246	1248	SG
O	1248	1249	®
O	1250	1253	was
O	1254	1261	applied
O	1262	1264	to
O	1265	1268	the
O	1269	1277	axillary
O	1278	1284	region
O	1285	1290	after
O	1291	1295	ALND
O	1295	1296	.

O	1297	1299	In
O	1300	1303	the
O	1304	1311	control
O	1312	1317	group
O	1318	1319	(
O	1319	1320	n
O	1321	1322	=
B-control-participants	1323	1325	46
O	1325	1326	)
O	1326	1327	,
O	1328	1332	ALND
O	1333	1336	was
O	1337	1346	performed
O	1347	1354	without
O	1355	1360	using
O	1361	1368	Guardix
O	1368	1369	-
O	1369	1371	SG
O	1371	1372	®
O	1372	1373	.

O	1374	1383	Comparing
B-outcome	1384	1387	ROM
I-outcome	1388	1391	for
I-outcome	1392	1400	shoulder
I-outcome	1401	1408	flexion
O	1409	1415	before
O	1416	1423	surgery
O	1424	1425	(
O	1425	1428	178
O	1428	1429	.
O	1429	1430	2
O	1430	1431	°
O	1431	1432	)
O	1433	1436	and
O	1437	1439	12
O	1440	1446	months
O	1447	1452	after
O	1453	1460	surgery
O	1461	1462	(
O	1462	1465	172
O	1465	1466	.
O	1466	1467	3
O	1467	1468	°
O	1468	1469	)
O	1469	1470	,
O	1471	1475	that
O	1476	1479	was
O	1480	1488	restored
O	1489	1491	12
O	1492	1498	months
O	1499	1504	after
O	1505	1512	surgery
O	1513	1515	in
O	1516	1519	the
O	1520	1527	Guardix
O	1527	1528	-
O	1528	1530	SG
O	1530	1531	®
O	1532	1537	group
O	1537	1538	,
O	1539	1542	and
O	1543	1548	there
O	1549	1552	was
O	1553	1555	no
O	1556	1569	statistically
O	1570	1581	significant
O	1582	1592	difference
O	1593	1600	between
O	1601	1605	that
O	1606	1608	at
O	1609	1615	before
O	1616	1623	surgery
O	1624	1627	and
O	1628	1630	12
O	1631	1637	months
O	1638	1643	after
O	1644	1651	surgery
O	1652	1653	(
O	1653	1654	p
O	1655	1656	=
O	1657	1658	0
O	1658	1659	.
O	1659	1662	182
O	1662	1663	)
O	1663	1664	.

B-outcome	1665	1667	No
I-outcome	1668	1675	adverse
I-outcome	1676	1682	effect
O	1683	1686	was
O	1687	1695	observed
O	1696	1698	in
O	1699	1705	either
O	1706	1711	group
O	1711	1712	.

O	1713	1716	The
O	1717	1724	results
O	1725	1727	of
O	1728	1732	this
O	1733	1738	study
O	1739	1743	have
O	1744	1749	shown
O	1750	1754	that
O	1755	1762	Guardix
O	1762	1763	-
O	1763	1765	SG
O	1765	1766	®
O	1767	1771	help
O	1772	1779	improve
O	1780	1788	shoulder
O	1789	1792	ROM
O	1793	1800	without
O	1801	1808	causing
O	1809	1816	adverse
O	1817	1824	effects
O	1825	1827	in
O	1828	1836	patients
O	1837	1840	who
O	1841	1850	underwent
O	1851	1857	breast
O	1858	1864	cancer
O	1865	1872	surgery
O	1872	1873	.

O	1874	1881	However
O	1881	1882	,
O	1883	1888	there
O	1889	1892	was
O	1893	1895	no
O	1896	1909	statistically
O	1910	1921	significant
O	1922	1932	difference
O	1933	1937	from
O	1938	1941	the
O	1942	1949	control
O	1950	1955	group
O	1955	1956	.

O	1957	1958	A
O	1959	1966	further
O	1967	1972	large
O	1972	1973	-
O	1973	1978	scale
O	1979	1984	study
O	1985	1987	is
O	1988	1994	needed
O	1995	1997	to
O	1998	2004	obtain
O	2005	2006	a
O	2007	2011	more
O	2012	2022	conclusive
O	2023	2033	conclusion
O	2033	2034	.

O	2035	2049	CRISKCT0003386
O	2049	2050	;
O	2051	2056	https
O	2056	2057	:
O	2057	2058	/
O	2058	2059	/
O	2059	2063	cris
O	2063	2064	.
O	2064	2067	nih
O	2067	2068	.
O	2068	2070	go
O	2070	2071	.
O	2071	2073	kr
O	2074	2075	(
O	2075	2083	20181207
O	2083	2084	)
O	2084	2085	.
